The approval of tirzepatide, the first dual incretin agonist, for the treatment of type 2 diabetes ushered in a “new

In type 2 diabetes, ARMMS-T2D is the largest and longest-running comparison of metabolic surgery versus medical and lifestyle intervention. In

This paper was presented on June 25 at the 83 American Diabetes Association ( ADA) Annual Scientific Session at San

This paper was presented on June 25 at the 83 American Diabetes Association ( ADA) Annual Scientific Session at San

According to new research, positive discordance as measured by a glycation ratio of glucose management indicator and haemoglobin A1c (GMI/A1c)

On June 26 2023, the American Diabetes Association® (ADA) presented Carmella Evans-Molina, MD, PhD, Eli Lilly Professor of Paediatric Diabetes,

In the symposium Engineering and Site Consideration for Cell Therapy on Monday, June 25, panellists discussed cell therapy and the

Approximately fifty percent of patients with endstage renal disease in developed countries have diabetes, according to the National Institutes of

There is accumulating evidence regarding the cardiovascular benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide 1 (GLP-1) receptor

This paper was presented by Drs Jean Lu, Cheng Yi Yuan, Yee W. Kong, Emma Netzer, Huanping Wu, Thomas Seidl,